Comparison of Three Treatments for Kaposi Sarcoma in Resource-Limited Settings

In a prospective randomized trial, paclitaxel plus ART had superior outcomes compared with two other widely used regimens for the treatment of AIDS-associated KS.

Kaposi sarcoma (KS) remains a common complication of AIDS in resource-limited settings and is seen even among HIV-infected persons with relatively intact immunity. Various chemotherapy regimens plus antiretroviral therapy (ART) are used for treatment, without consensus on a preferred regimen. The AIDS Clinical Trials Group has now conducted a noninferiority study at 11 sites in Africa and South America, randomizing patients with advanced AIDS-related KS 1:1:1 to three different regimens (all combined with ART, which consisted of efavirenz, tenofovir [TDF], and emtricitabine [FTC]): intravenous (IV) bleomycin plus vincristine, oral etoposide, or IV paclitaxel (the control). The primary outcome was progression-free survival at week 48 (PFS; d…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Comparison of Three Treatments for Kaposi Sarcoma in Resource-Limited Settings

Topics

Reviewing Author